These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 3965500)

  • 1. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
    Donaldson VH; Harrison RA; Rosen FS; Bing DH; Kindness G; Canar J; Wagner CJ; Awad S
    J Clin Invest; 1985 Jan; 75(1):124-32. PubMed ID: 3965500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary and acquired deficiencies of C1 inhibitor.
    Davis AE
    Immunodefic Rev; 1989; 1(3):207-26. PubMed ID: 2698641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.
    Cugno M; Nuijens J; Hack E; Eerenberg A; Frangi D; Agostoni A; Cicardi M
    J Clin Invest; 1990 Apr; 85(4):1215-20. PubMed ID: 2318974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1-inhibitor--biochemical properties and clinical applications.
    Al-Abdullah IH; Greally J
    Crit Rev Immunol; 1985; 5(4):317-30. PubMed ID: 3899511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of C1(-)-inhibitors from normal persons and patients with type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa).
    Donaldson VH; Mitchell BH; Everson B; Ratnoff OD
    Blood; 1990 Feb; 75(4):911-21. PubMed ID: 2302459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.
    Harpel PC; Hugli TE; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):605-11. PubMed ID: 123252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.
    Kramer J; Katz Y; Rosen FS; Davis AE; Strunk RC
    J Clin Invest; 1991 May; 87(5):1614-20. PubMed ID: 1902490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.
    Quastel M; Harrison R; Cicardi M; Alper CA; Rosen FS
    J Clin Invest; 1983 Apr; 71(4):1041-6. PubMed ID: 6833491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.
    Jackson J; Sim RB; Whaley K; Feighery C
    J Clin Invest; 1989 Feb; 83(2):698-707. PubMed ID: 2536404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
    Wisnieski JJ; Knauss TC; Yike I; Dearborn DG; Narvy RL; Naff GB
    J Immunol; 1994 Mar; 152(6):3199-209. PubMed ID: 8144914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema.
    Cicardi M; Igarashi T; Kim MS; Frangi D; Agostoni A; Davis AE
    J Clin Invest; 1987 Dec; 80(6):1640-3. PubMed ID: 2890659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.
    Curd JG; Yelvington M; Ziccardi RJ; Mathison DA; Griffin JH
    Clin Exp Immunol; 1981 Aug; 45(2):261-70. PubMed ID: 6976242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    Harpel PC; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remissions induced in hereditary angioneurotic edema with an attenuated androgen (danazol): correlation between concentrations of C1-inhibitor and the forth and second components of complement.
    Pitts JS; Donaldson VH; Forristal J; Wyatt RJ
    J Lab Clin Med; 1978 Oct; 92(4):501-7. PubMed ID: 712189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency.
    Smith MA; Kerr MA
    Immunology; 1985 Nov; 56(3):561-70. PubMed ID: 2934317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema.
    Cicardi M; Igarashi T; Rosen FS; Davis AE
    J Clin Invest; 1987 Mar; 79(3):698-702. PubMed ID: 3818946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.
    He S; Sim RB; Whaley K
    Mol Med; 1998 Feb; 4(2):119-28. PubMed ID: 9508789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes.
    Wallace EM; Perkins SJ; Sim RB; Willis AC; Feighery C; Jackson J
    Mol Med; 1997 Jun; 3(6):385-96. PubMed ID: 9234243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid method for functional determination of C1 esterase inhibitor in plasma.
    Cullmann W; Kövary PM; Dick W; Czarnetzki B; Echternach-Happle K
    Clin Chim Acta; 1982 Mar; 119(3):237-42. PubMed ID: 6175450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.